Zurueck zur Suche

Reporte zur Charge UT7683MA

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

4Reporte angezeigt
0Todesfaelle
1Hospitalisiert
1Lebensbedrohlich
0Bleibende Schaeden
FL 3 MS 1

VAERS 2500716

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE QUADRIVALENT) · Charge UT7683MA

schwer
Staat
FL
Alter
51,0
Geschlecht
M
Eingang
07.11.2022
Impfdatum
06.10.2022
Beginn
01.11.2022
Tage bis Beginn
26,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: ja Hospital: ja Disable: unbekannt ER: unbekannt Erholt: nein
COVID-19 Guillain-Barre syndrome SARS-CoV-2 test positive

Symptomtext

Fluzone vaccine delivered 10/6/22. Resident tested positive for Covid 19 10/11/22 and was sent to hospital 10/12/22. Hospital records show GBS (Guillain Barre Syndrome)

Weitere VAERSDATA-Felder
Praegender Schweregrund
Guillain-Barre syndrome
Hospital-Tage
26,0
Labordaten
-
Aktuelle Erkrankungen
DM Type 2 WITH DIABETIC NEUROPATHY, UNSPECIFIED (E11.40) Hypercholestremia
Vorgeschichte
DM Type 2 WITH DIABETIC NEUROPATHY, UNSPECIFIED (E11.40) TYPE 2 DIABETES MELLITUS WITH UNSPECIFIED COMPLICATIONS Lower back pain HEMIPLEGIA AND HEMIPARESIS FOLLOWING CEREBRAL INFARCTION AFFECTING RIGHT DOMINANT SIDE CARDIOMEGALY CHRONIC PULMONARY EDEMA MUSCLE WEAKNESS (GENERALIZED)
Andere Medikamente
Amoxicillin-Pot Clavulanate Tablet 875-125 MG Spironolactone Tablet 25 MG Sertraline HCl Tablet 25 MG Coreg Tablet 12.5 MG (Carvedilol Lasix Tablet 20 MG Glucagon Emergency Kit 1 MG (Glucagon (rDNA)) Albuterol Sulfate Nebulization Solut
Allergien
No known allergies
Vorherige Impfungen
-

VAERS 2508508

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE QUADRIVALENT) · Charge ut7683MA

mild
Staat
FL
Alter
16,0
Geschlecht
F
Eingang
15.11.2022
Impfdatum
08.11.2022
Beginn
13.11.2022
Tage bis Beginn
5,0
Dosis
UNK
Route/Site
IM / LL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site erythema Injection site warmth

Symptomtext

large circular red marking to right upper arm , warm to touch

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
NKA
Vorherige Impfungen
-

VAERS 2467739

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE QUADRIVALENT) · Charge UT7683MA

mild
Staat
MS
Alter
57,0
Geschlecht
M
Eingang
03.10.2022
Impfdatum
29.09.2022
Beginn
30.09.2022
Tage bis Beginn
1,0
Dosis
N/A
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Chills Pain Pyrexia

Symptomtext

fever, chils, body aches

Weitere VAERSDATA-Felder
Praegender Schweregrund
Chills
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2495933

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE QUADRIVALENT) · Charge UT7683MA

gering
Staat
FL
Alter
0,3
Geschlecht
M
Eingang
02.11.2022
Impfdatum
24.10.2022
Beginn
24.10.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / LL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Medication error No adverse event Product administered to patient of inappropriate age

Symptomtext

4 month old patient received a dose of FLUZONE QUAD QIV with no reported adverse event; Initial information received on 24-Oct-2022 regarding an unsolicited valid non-serious case received from medical assistant and physician. This case involves a 4-month-old male patient who received a dose of INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QIV] with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included PNEUMOCOCCAL VACCINE CONJ 7V (CRM197) (PREVNAR) for Immunization; DIPHTHERIA VACCINE TOXOID, HEPATITIS B VACCINE RHBSAG (YEAST), PERTUSSIS VACCINE ACELLULAR 3-COMPONENT, POLIO VACCINE INACT 3V (VERO), TETANUS VACCINE TOXOID (PEDIARIX) for Immunization; ROTAVIRUS VACCINE (ROTAVIRUS VACCINE) for Immunization; and HIB VACCINE (HIB) for Immunization. On 24-Oct-2022, the 4-month-old patient received suspect INFLUENZA QUADRIVAL A-B VACCINE at (unknown: formulation, strength) at dose 0.5ml once (lot: UT7683MA, expiry date: 30-Jun-2023) via intramuscular route in the left thigh for immunization with no reported adverse event (product administered to patient of inappropriate age) at same day latency. Action taken: Not applicable. No corrective treatment was received for the event. At time of reporting, the outcome was Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Medication error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
PREVNAR; PEDIARIX; ROTAVIRUS VACCINE; HIB
Allergien
-
Vorherige Impfungen
-